Literature DB >> 1106917

Clinical applications of the continuous flow blood separator machine.

C J Oon, J R Hobbs.   

Abstract

The NCl/IBM or Aminco Continuous Flow Blood Separator Machine is a safe apparatus for the selective removal or exchange of either packed red blood cells, leucocyte-rich or platelet-rich layers or plasma. Abnormal fractions from any of these layers may be collected and discarded. Normal constituents may be collected for therapeutic uses. The wide scope of its applications includes important uses in clinical immunology: temporary provision of good leucocytes or platelets; harvesting of immune leucocytes (preparation of transfer factor at up to 10 units per harvest); removal of cryo- or macro-globulins, immune complexes or blocking factors; replacement therapy for antibody or complement deficiencies. Examples are given of such uses together with some of the medical problems so far encountered.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1106917      PMCID: PMC1538178     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Bone-marrow transplantation for hematologic neoplasia in 16 patients with identical twins.

Authors:  A Fefer; A B Einstein; E D Thomas; C D Buckner; R A Clift; H Glucksberg; P E Neiman; R Storb
Journal:  N Engl J Med       Date:  1974-06-20       Impact factor: 91.245

2.  Improved granulocyte procurement with the continuous flow centrifuge.

Authors:  R A Clift; C D Buckner; B M Williams; R O Hickman; E D Thomas
Journal:  Transfusion       Date:  1973 Sep-Oct       Impact factor: 3.157

3.  Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria.

Authors:  R G Graw; G Herzig; S Perry; E S Henderson
Journal:  N Engl J Med       Date:  1972-08-24       Impact factor: 91.245

4.  Immunological features in a case of chronic granulomatous candidiasis and its treatment with transfer factor.

Authors:  H Valdimarsson; C B Wood; J R Hobbs; P J Holt
Journal:  Clin Exp Immunol       Date:  1972-06       Impact factor: 4.330

5.  Proceedings: Immunotherapy of malignant disease: the use of viable sensitized lymphocytes or transfer factor prepared from sensitized lymphocytes.

Authors:  E T Krementz; P W Mansell; M O Hornung; M S Samuels; C A Sutherland; E N Benes
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

6.  Controlled trial of exchange-transfusion therapy in fulminant hepatitis.

Authors:  A G Redeker; H S Yamahiro
Journal:  Lancet       Date:  1973-01-06       Impact factor: 79.321

7.  Management of adult acute myelogenous leukaemia.

Authors:  D Crowther; R L Powles; C J Bateman; M E Beard; C L Gauci; P F Wrigley; J S Malpas; G H Fairley; R B Scott
Journal:  Br Med J       Date:  1973-01-20

Review 8.  Transfer factor.

Authors:  H S Lawrence
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

9.  Method of removing abnormal protein rapidly from patients with malignant paraproteinaemias.

Authors:  R Powles; C Smith; J Kohn; G Hamilton Fairley
Journal:  Br Med J       Date:  1971-09-18

10.  Serum mediated inhibition of the immunological reactions of the patient to his own tumour: a possible role for circulating antigen.

Authors:  G A Currie; C Basham
Journal:  Br J Cancer       Date:  1972-12       Impact factor: 7.640

View more
  6 in total

1.  Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?

Authors:  Robert Peter Gale; Charles A Schiffer; Hillard M Lazarus
Journal:  Bone Marrow Transplant       Date:  2021-07-03       Impact factor: 5.483

2.  Leucapheresis in severe rheumatoid arthritis.

Authors:  J Tenenbaum; M B Urowitz; E C Keystone; I L Dwosh; J E Curtis
Journal:  Ann Rheum Dis       Date:  1979-02       Impact factor: 19.103

3.  Influence of continuous-flow blood separator leucophoresis on in vitro functions of human lymphocytes.

Authors:  H C Siewertsen; H H Peter; J R Kalden; J Wysk; G Eckert; S Oehl; U W Schäfer; H Deicher
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

4.  Lymphapheresis as compared with rest period in treatment of severe rheumatoid arthritis.

Authors:  A M Boerbooms; D J De Rooy; P J Geerdink; L B Van de Putte; F A Van den Ouweland
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980

5.  Continuous-flow plasmapheresis in management of severe rhesus disease.

Authors:  J Graham-Pole; W Barr; M L Willoughby
Journal:  Br Med J       Date:  1977-05-07

Review 6.  P.R.L. platelet rich lipotransfert: our experience and current state of art in the combined use of fat and PRP.

Authors:  V Cervelli; I Bocchini; C Di Pasquali; B De Angelis; G Cervelli; C B Curcio; A Orlandi; M G Scioli; E Tati; P Delogu; Pietro Gentile
Journal:  Biomed Res Int       Date:  2013-09-28       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.